Witty says GSK must change as strategic shift is outlined GlaxoSmithKline has posted an unspectacular set of financial results for the second quarter but this has been overshadowed by the firm setting out a major strategic shift to focus less on looking for blockbusters and build up its vaccine and...
GlaxoSmithKline earnings hurt by generics, Avandia Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.That's down from 1.33 billion pounds a year earlier.
Sales grew slightly, inching to 5.9 billion pounds ($11.7 billion) from 5.7 billion pounds.
But...
GlaxoSmithKline earnings hurt by generics, Avandia Competition from generic drugs weighed on GlaxoSmithKline's bottom line in the second quarter, the pharmaceutical company said Wednesday.Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.That's down from...
GlaxoSmithKline earnings hurt by generics, Avandia Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.That's down from 1.33 billion pounds a year earlier.
Sales grew slightly, inching to 5.9 billion pounds ($11.7 billion) from 5.7 billion pounds.
But...
GlaxoSmithKline 2Q earnings hurt by generics, Avandia Competition from generic drugs weighed on GlaxoSmithKline's bottom line in the second quarter, the pharmaceutical company said Wednesday.Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.
That's down...
GlaxoSmithKline second-quarter profit slips on competition LONDON - GlaxoSmithKline PLC, the world's second-largest drug maker, posted a three per cent drop in second-quarter profit on Wednesday, after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job...
GlaxoSmithKline 2Q earnings hurt by generics, Avandia Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.That's down from 1.33 billion pounds a year earlier.
Sales grew slightly, inching to 5.9 billion pounds ($11.7 billion) from 5.7 billion pounds.
But...
GlaxoSmithKline earnings hurt by generics, Avandia Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.That's down from 1.33 billion pounds a year earlier.
Sales grew slightly, inching to 5.9 billion pounds ($11.7 billion) from 5.7 billion pounds.
But...
GlaxoSmithKline second-quarter profit slips on competition LONDON - GlaxoSmithKline PLC, the world's second-largest drug maker, posted a three per cent drop in second-quarter profit on Wednesday, after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job...
GlaxoSmithKline earnings hurt by generics, Avandia Glaxo (NYSE: GSK) said it earned 1.29 billion pounds ($2.56 billion) in the quarter.That's down from 1.33 billion pounds a year earlier.
Sales grew slightly, inching to 5.9 billion pounds ($11.7 billion) from 5.7 billion pounds.
But...
Glaxo second-quarter earns down 3 percent as generic competition continues to bite As rising generic sales continue to eat away at its profits, Glaxo also unveiled plans to grab a share of that market itself, announcing an alliance with South African company Aspen Pharmacare Holdings.Glaxo reported that net profit fell...
GlaxoSmithKline second-quarter profit slips on competition LONDON - GlaxoSmithKline PLC, the world's second-largest drug maker, posted a three per cent drop in second-quarter profit on Wednesday, after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job...
GlaxoSmithKline 2Q profit slips on competition LONDON - GlaxoSmithKline PLC, the world's second-largest drug maker, posted a 3 percent drop in second-quarter profit on Wednesday, after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job cuts.
GlaxoSmithKline 2Q profit slips on competition As rising generic sales continue to eat away at its profits, Glaxo also unveiled plans to grab a share of that market itself, announcing an alliance with South African company Aspen Pharmacare Holdings.Glaxo reported that profit fell to 1...
Varenicline safety concerns: An interview with Dr Serena Tonstad In the midst of the varenicline (Chantix, Pfizer) controversy, perhaps we should just ask the experts who've already studied thousands of patients about their experiences.If this compound can make one into both a Dr Jekyll and Mr Hyde,...
KV Pharmaceutical Company Reports Fiscal 2008 Results LOUIS, June 16 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company , a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and generic/non-branded prescription...
GSK announces new drug application & phase III results for Rezoni/Zunrisa GlaxoSmithKline (GSK) announced the submission of a new drug application to the US Food and Drug Administration and new data from two phase III trials for Rezonic/Zunrisa (casopitant), a novel, investigational NK-1 receptor antagonist.The...
UPDATE 1-Glaxo seeks U.S. approval for anti-nausea drug (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) said on Thursday it had submitted its new anti-nausea drug Rezonic for approval in the United States, and presented fresh clinical data supporting the medicine's effectiveness...
Diagnosis: Cancer, but hope evolving Four years ago, Linda Martin's life turned upside down.During a routine examination, her gynecologist found a lump in one of her breasts.
A mammogram indicated the growth was benign, but Martin's gut told her otherwise.
She insisted a...
